Thyrocare Technologies Limited
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology. The Imaging Services segment sells radio-pharmaceutical an… Read more
Thyrocare Technologies Limited - Asset Resilience Ratio
Thyrocare Technologies Limited (THYROCARE) has an Asset Resilience Ratio of 22.52% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how Thyrocare Technologies Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Thyrocare Technologies Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹315.40 Million | 4.64% |
| Short-term Investments | ₹1.22 Billion | 17.88% |
| Total Liquid Assets | ₹1.53 Billion | 22.52% |
Asset Resilience Insights
- Good Liquidity Position: Thyrocare Technologies Limited maintains a healthy 22.52% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Thyrocare Technologies Limited Industry Peers by Asset Resilience Ratio
Compare Thyrocare Technologies Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Thyrocare Technologies Limited (2012–2025)
The table below shows the annual Asset Resilience Ratio data for Thyrocare Technologies Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 27.67% | ₹1.92 Billion | ₹6.93 Billion | +0.24pp |
| 2024-03-31 | 27.43% | ₹1.77 Billion | ₹6.44 Billion | +3.60pp |
| 2023-03-31 | 23.83% | ₹1.51 Billion | ₹6.33 Billion | +0.98pp |
| 2022-03-31 | 22.85% | ₹1.39 Billion | ₹6.08 Billion | +1.29pp |
| 2021-03-31 | 21.56% | ₹1.18 Billion | ₹5.46 Billion | +4.50pp |
| 2020-03-31 | 17.07% | ₹801.00 Million | ₹4.69 Billion | -0.68pp |
| 2019-03-31 | 17.75% | ₹842.40 Million | ₹4.75 Billion | -5.64pp |
| 2018-03-31 | 23.39% | ₹1.12 Billion | ₹4.79 Billion | -2.17pp |
| 2017-03-31 | 25.55% | ₹1.11 Billion | ₹4.36 Billion | +3.19pp |
| 2016-03-31 | 22.37% | ₹916.31 Million | ₹4.10 Billion | -3.21pp |
| 2015-03-31 | 25.58% | ₹843.01 Million | ₹3.30 Billion | -15.68pp |
| 2014-03-31 | 41.26% | ₹1.01 Billion | ₹2.46 Billion | +10.93pp |
| 2013-03-31 | 30.33% | ₹596.03 Million | ₹1.97 Billion | +30.04pp |
| 2012-03-31 | 0.29% | ₹4.00 Million | ₹1.37 Billion | -- |